Home > Insider Trading > Filing (0001567619-21-018627)

Filing Details

Accession Number:: 0001567619-21-018627
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-10-22 21:36:35
Reporting Period:: 2021-10-20

Accepted Time:: 2021-10-22 21:36:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1630627	Treace Medical Concepts Inc.	TMCI	Surgical & Medical Instruments & Apparatus (3841)	471052611

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1856380	T. John Treace	C/O Treace Medical Concepts, Inc. 203 Fort Wade Road, Suite 150 Ponte Vedra FL 32081	Chief Executive Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-10-20	22,612	$24.79	5,894,968	No	4	S	Direct
Common Stock	Disposition	2021-10-20	8,215	$25.37	5,886,753	No	4	S	Direct
Common Stock	Disposition	2021-10-21	34,325	$19.89	5,852,428	No	4	S	Direct
Common Stock	Disposition	2021-10-21	26,701	$20.67	5,825,727	No	4	S	Direct
Common Stock	Disposition	2021-10-21	2,768	$21.49	5,822,959	No	4	S	Direct
Common Stock	Disposition	2021-10-21	8,207	$23.07	5,814,752	No	4	S	Direct
Common Stock	Disposition	2021-10-21	4,044	$23.86	5,810,708	No	4	S	Direct
Common Stock	Disposition	2021-10-21	39	$24.50	5,810,669	No	4	S	Direct
Common Stock	Disposition	2021-10-22	57,534	$20.74	5,753,135	No	4	S	Direct
Common Stock	Disposition	2021-10-22	555	$21.16	5,752,580	No	4	S	Direct
Common Stock	Acquisiton	2021-09-07	408,816	$0.00	408,816	No	4	A	Indirect	As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Indirect	As Co-Trustee of the John R. Treace Irrevocable Trust dated July 29, 2021

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,605,000	Indirect	By Wife
Common Stock	1,471,250	Indirect	By Wife as cotrustee of the JTT Irrevocable Trust dated September 30, 2020
Common Stock	1,839,063	Indirect	As Trustee of the Tracy W. Treace Irrevocable Trust dated September 25, 2020

Footnotes

Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.21 to $25.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.22 to $25.69 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.21 to $20.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.22 to $21.16 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.98 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.37 to $23.36 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.38 to $24.25 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.12 to $21.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.14 to $21.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, uponrequest, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee.